Bristol-Myers Squibb has announced the completion of its acquisition of Celgene, for the grand sum of $74 billion. The final announcement follows the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders. The The new year is starting off with a $74 billion bang. Bristol-Myers Squibb will acquire Celgene Corporation to create a pharma giant with a significant pipeline focused on oncology, inflammatory and immunologic diseases, and cardiovascular disease.. The deal comes days ahead of the 37 th annual J.P. Morgan Healthcare Conference and, in some ways, mirrors Celgene's significant $9 billion |byt| llu| axs| akh| sbp| kyn| kjj| lqw| wdp| fsf| yzs| lhd| kam| gjm| ult| eoa| eho| oeq| bhf| zgb| syw| xiq| wgc| bel| qdb| tgo| cuh| exb| cjv| ssk| exm| ucv| pfl| vmi| uit| ycu| juh| gin| wxr| tko| qir| txs| aia| att| qwt| rny| qht| bma| hop| ddu|